A Phase III, open label, randomised, 3-Arm, multi-centre study of Savolitinib plus Durvalumab versus Sunitinib and Savolitinib and Durvalumab Monotherapy in Participants with MET- driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma (PRCC) [SAMETA].

  • Frydenberg, Mark (Primary Chief Investigator (PCI))
  • Spence, Anne (Project Manager)

Project: Research

Project Details

Effective start/end date20/01/2231/12/25


  • Medical oncology
  • Clinical trial